Le Lézard
Classified in: Business
Subject: MERGERS AND ACQUISITIONS (M&A)

Brompton Proposes Merger Of Taylor North American Equity Opportunities Fund with Brompton Global Dividend Growth ETF


TORONTO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- (TSX: TOF.UN) Brompton Funds Limited ("Brompton" or the "Manager"), the Manager of Taylor North American Equity Opportunities Fund (the "Fund") announces that it is calling a special meeting (the "Meeting") of holders (the "Unitholders") of units (the "Units") of the Fund.  Given the small size of the Fund, it is becoming increasingly difficult to efficiently execute the Fund's investment strategy and maintain portfolio diversification and maintain a reasonable management expense ratio.  The purpose of the Meeting, therefore, is to consider the merger of the Fund with Brompton Global Dividend Growth ETF ("Global Dividend Growth ETF"), with Global Dividend Growth ETF being the continuing fund (the "Merger").  Global Dividend Growth ETF is expected to be listed on the Toronto Stock Exchange starting on October 18, 2018 and is focused on investing in an actively managed portfolio composed of large capitalization global equities that have a history of or, in the Manager's view, potential for, dividend growth.  Its investment objectives are to provide unitholders with: (a) stable monthly cash distributions; (b) the opportunity for capital appreciation; and (c) lower overall volatility of portfolio returns than would otherwise be experienced by owning securities of global dividend growth companies directly.  All costs of the Merger, including with respect to the Meeting, will be borne by the Manager.

The Manager believes that the Merger, if approved by the Fund's Unitholders, provides Unitholders with the following benefits:

As a result of the proposed Merger, the Fund expects to offer an accelerated annual redemption on December 28, 2018, payable on January 15, 2019. 

The Fund will hold a special meeting of Unitholders on November 30, 2018 to consider and vote on the proposed Merger.  Unitholders of record at the close of business on October 31, 2018 will be entitled to vote at the Meeting.  The proposed Merger will be subject to any required regulatory approvals and the Manager expects the effective date of the Merger to take place on or about January 16, 2019.  Details of the proposed Merger will be further outlined in the Fund's notice of meeting and management information circular that will be prepared and delivered to Unitholders in connection with the special meeting and will be available on www.sedar.com.

About Brompton Funds
Brompton Funds, a division of Brompton Group which was founded in 2000, is an experienced investment fund manager with over $2 billion in assets under management. Brompton's investment solutions include TSX traded funds, mutual funds and flow-through limited partnerships.  For further information, please contact your investment advisor, call Brompton's investor relations line at 416-642-6000 (toll-free at 1-866-642-6001), email [email protected] or visit our website at www.bromptongroup.com.

You will usually pay brokerage fees to your dealer if you purchase or sell units of an investment fund on the Toronto Stock Exchange or other alternative Canadian trading system (an "exchange").  If the units are purchased or sold on an exchange, investors may pay more than the current NAV when buying units of an investment fund and may receive less than the current NAV when selling them.

There are ongoing fees and expenses associated with owning units of an investment fund.  An investment fund must prepare disclosure documents that contain key information about the fund.  You can find more detailed information about the fund in the public filings available at www.sedar.com.  Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

Certain statements contained in this news release constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to matters disclosed in this press release and to other matters identified in public filings relating to the Fund and Global Dividend Growth ETF, to the future outlook of the Fund and Global Dividend Growth ETF and anticipated events or results and may include statements regarding the future financial performance of the Fund and Global Dividend Growth ETF.  In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "intend", "estimate", "predict", "potential", "continue" or other similar expressions concerning matters that are not historical facts.  Actual results may vary from such forward-looking information. Investors should not place undue reliance on forward-looking statements.  These forward-looking statements are made as of the date hereof and we assume no obligation to update or revise them to reflect new events or circumstances.


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:39
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:35
Regenx Tech Corp., (the "Company" or "Regenx") is providing this bi-weekly update on the status of the application to the Alberta Securities Commission for a management cease trade order, under National Policy 12-203 -?? Management Cease Trade...

at 19:14
Kadestone Capital Corp. ("Kadestone" or the "Company") , a vertically integrated property company today announced its financial results for the year ended December 31, 2023....

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...



News published on and distributed by: